Minerva Neurosciences, Inc. (NERV)
| Market Cap | 78.61M |
| Revenue (ttm) | 41.18M |
| Net Income (ttm) | 5.29M |
| Shares Out | 42.72M |
| EPS (ttm) | 0.13 |
| PE Ratio | 14.49 |
| Forward PE | 11.21 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $1.84 |
| Previous Close | $1.87 |
| Change ($) | -0.03 |
| Change (%) | -1.60% |
| Day's Open | 1.85 |
| Day's Range | 1.83 - 1.89 |
| Day's Volume | 214,120 |
| 52-Week Range | 1.80 - 4.12 |
Analysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for
Minerva Neurosciences (NERV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Management to host conference call Management to host conference call
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat centr...
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat centra...
Minerva Neurosciences (NERV) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
Looking for penny stocks to buy during a market correction? Check these 4 out for your watchlist The post Best Penny Stocks to Buy During a Market Correction?
Biotech penny stocks are heating up right now; here's 4 to watch The post Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May appeared first on Penny Stocks to Buy, Picks, News and Informat...
Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boos...
Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, impr...
WALTHAM, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous s...
Management to host conference call Management to host conference call
Investors need to pay close attention to Minerva Neurosciences (NERV) stock based on the movements in the options market lately.
Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021
LOS ANGELES, Feb. 8, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosciences, Inc. ("Minerva...
New York, New York--(Newsfile Corp. - February 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...
New York, New York--(Newsfile Corp. - February 8, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) betwe...
Los Angeles, California--(Newsfile Corp. - February 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosci...
Los Angeles, California--(Newsfile Corp. - February 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Minerva Neurosci...
NEW YORK, Feb. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and...
New York, New York--(Newsfile Corp. - February 5, 2021) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" ...
New York, New York--(Newsfile Corp. - February 4, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...
Boston, Massachusetts--(Newsfile Corp. - February 3, 2021) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of Minerva Neurosciences, Inc. (NASDAQ: NER...
NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class a...
NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NE...
New York, New York--(Newsfile Corp. - February 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...
New York, New York--(Newsfile Corp. - February 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...
New York, New York--(Newsfile Corp. - February 2, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NER...
Click here to join the case
NEW YORK, Jan. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NERV) and certain of ...
New York, New York--(Newsfile Corp. - January 29, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...
New York, New York--(Newsfile Corp. - January 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...
BOSTON, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it has filed a class action lawsuit on behalf of share...
NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15...
NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NE...
New York, New York--(Newsfile Corp. - January 23, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between M...
New York, New York--(Newsfile Corp. - January 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and Nov...
New York, New York--(Newsfile Corp. - January 21, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...
New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NER...
New York, New York--(Newsfile Corp. - January 20, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...
New York, New York--(Newsfile Corp. - January 20, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Minerva Neurosciences, Inc. (NASDAQ: NERV...
NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15...
New York, New York--(Newsfile Corp. - January 19, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ...
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...
NEW YORK, NY / ACCESSWIRE / January 19, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. ...
NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and...
New York, New York--(Newsfile Corp. - January 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of M...
NEW YORK, NY / ACCESSWIRE / January 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
About NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma C... [Read more...]
| Industry Biotechnology | IPO Date Jul 1, 2014 |
| CEO Remy Luthringer | Employees 11 |
| Stock Exchange NASDAQ | Ticker Symbol NERV |
Analyst Forecasts
According to 6 analysts, the average rating for NERV stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 280.43% from the latest price.